54828-05-6 Usage
Description
1-METHYL-4-NITRO-1H-IMIDAZOLE-5-CARBOXYLIC ACID is a chemical compound belonging to the imidazole family, characterized by its unique molecular structure featuring a methyl group, a nitro group, and a carboxylic acid functional group. This derivative possesses specific chemical properties that make it a valuable intermediate in the synthesis of various organic compounds.
Uses
Used in Pharmaceutical Industry:
1-METHYL-4-NITRO-1H-IMIDAZOLE-5-CARBOXYLIC ACID is used as a key intermediate in the synthesis of heteroxanthine, a compound with potential applications in the development of pharmaceuticals. Its unique structure allows for the creation of new drug candidates that can target specific biological pathways or receptors, contributing to the advancement of medicine and healthcare.
In the synthesis of heteroxanthine, 1-METHYL-4-NITRO-1H-IMIDAZOLE-5-CARBOXYLIC ACID plays a crucial role as a building block, enabling the formation of complex molecules with diverse therapeutic properties. Its versatility in chemical reactions and compatibility with other molecular components make it an essential component in the design and production of innovative pharmaceutical agents.
Check Digit Verification of cas no
The CAS Registry Mumber 54828-05-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,8,2 and 8 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 54828-05:
(7*5)+(6*4)+(5*8)+(4*2)+(3*8)+(2*0)+(1*5)=136
136 % 10 = 6
So 54828-05-6 is a valid CAS Registry Number.
InChI:InChI=1/C5H5N3O4/c1-7-2-6-4(8(11)12)3(7)5(9)10/h2H,1H3,(H,9,10)
54828-05-6Relevant articles and documents
AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF
-
Paragraph 0151; 0153, (2020/09/19)
The present disclosure relates generally to aromatic derivatives that are inhibitors of FGFR4 and are useful in treating FGFR4-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also provided.
ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2
Kiselyov, Alexander S.,Piatnitski, Evgueni L.,Samet, Alexander V.,Kisliy, Victor P.,Semenov, Victor V.
, p. 1369 - 1375 (2007/10/03)
We have developed a series of novel potent ortho-substituted azole derivatives active against kinases VEGFR-1 and VEGFR-2. Both specific and dual ATP-competitive inhibitors of VEGFR-2 were identified. Kinase activity and selectivity could be controlled by varying the arylamido substituents at the azole ring. The most specific molecule (17) displayed >10-fold selectivity for VEGFR-2 over VEGFR-1. Compound activities in enzymatic and cell-based assays were in the range of activities for reported clinical and development candidates (IC50 30 × 10-5 cm/min) is indicative of their potential for intestinal absorption upon oral administration.
The Synthesis of Ring-expanded Analogues of Xanthine Containing the Imidazodiazepine Ring System
Hosmane, Ramachandra S.,Bhan, Anila
, p. 2189 - 2196 (2007/10/02)
The synthesis of 4,5,7,8-tetrahydro-6H-imidazodiazepine-5,8-dione and its several 1- and 3-alkyl (aralkyl) derivatives 2 has been reported.Mechanistic explorations of the final synthetic step as well as structural confirmation of a final produ
